Ildong, CoLucid sign distribution and supply agreement for lasmiditan, a novel agent for acute migra

Published: 2013-10-25 06:57:00

Updated: 2013-10-25 06:57:00

Ildong Pharmaceutical said Wednesday that it has signed distribution and supply agreement with the U.S.-based CoLucid Pharmaceuticals for lasmiditan in Southeast Asia as well as Korea.

Under the agreement, CoLucid will receive upfront and milestone payments in addition to consideration for product supply in exchange for exclusive rights to Ildong for development and commercialization of lasm...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.